Results 111 to 120 of about 616,871 (170)

Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models.

open access: yesBlood
Miao H   +28 more
europepmc   +1 more source

Nucleoporin 98 Rearrangements in Acute Leukemia: A Genomic Landscape Study. [PDF]

open access: yesHematol Oncol
Batayneh O   +10 more
europepmc   +1 more source

The tumor suppressor menin is a key scaffold mediator for homologous recombination repair. [PDF]

open access: yesNucleic Acids Res
Lian A   +8 more
europepmc   +1 more source

Introduzione. La filosofia del «promeneur solitaire»

open access: yes, 2017
Marco Menin, Lorenzo Rustighi
core  

The role of menin inhibitors in acute myeloid leukemia

open access: yesCurrent Opinion in Oncology
Purpose of review Acute myeloid leukemia (AML) characterized by NPM1 mutations or KMT2A rearrangements depends on abnormal epigenetic programs mediated by menin, a critical scaffold protein for sustaining the expression of oncogenic HOX/MEIS1 genes. Therefore, menin inhibitors have become a promising class of AML treatments.
Isidori A., Marconi G.
openaire   +4 more sources

Menin Inhibitor Induced Menin Protein Degradation Contributes to Menin Inhibitor Efficacy

Blood, 2023
The chromatin adaptor protein Menin ( MEN1) is necessary for sustained proliferation in acute leukemias driven either by Lysine Methyltransferase 2A (MLL1/ KMT2A) gene rearrangements. Small molecule Menin inhibitors (MIs) disrupt the MENIN-KMT2A protein interaction by competing with KMT2A for a binding pocket in Menin.
Jevon Cutler   +12 more
openaire   +1 more source

Home - About - Disclaimer - Privacy